Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSALLO posaconazole prophylaxis after allo-HSC
2024-511507-42-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of posaconazole in invasive mycoses, sponsored by CHU de Nantes. Primary endpoint: Residual plasma posaconazole concentration on day 8. Planned start Nov 2024; status: authorised.
02
Drugs
posaconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on 2024-511507-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511507-42-00.